Subjects: CCA, FVT
Aethlon Medical To Release Second Quarter Financial Results and Host Conference Call on October 28, 2020
SAN DIEGO, Oct. 19, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its second quarter fiscal year 2021, ended September 30, 2020, at 4:15 pm Eastern time on Wednesday, October 28, 2020.
Management will host a conference call on Wednesday, October 28, 2020 at 4:30 pm eastern time to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.
Interested parties can register for the conference by navigating to https://dpregister.com/sreg/10149369/dbcc2bc6ad. Please note that registered participants will receive their dial in number upon registration.
Interested parties without internet access or unable to pre-register may dial in by calling: | |
PARTICIPANT DIAL IN (TOLL FREE): | 1-844-836-8741 |
PARTICIPANT INTERNATIONAL DIAL IN: | 1-412-317-5442 |
All callers should ask for the Aethlon Medical, Inc. conference call. | |
A replay of the call will be available approximately one hour after the end of the call through November 4, 2020. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10149369.
About Aethlon Medical, Inc.
Aethlon Medical is focused on addressing unmet needs in global health. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier® depletes the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The Hemopurifier® is an FDA designated "Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies.
Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
[email protected]
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
[email protected]
212-845-4251
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
[email protected]
212-966-3650
SOURCE Aethlon Medical, Inc.
These press releases may also interest you
|
News published on and distributed by:
